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Despite improvements in early survival after an acute myocardial infarction (MI), the incidence 
of heart failure in the longer term remains persistently high [1,2]. This conundrum is vexing. On 
the one hand, the epidemiology reflects the advances in acute cardiovascular care and secondary 
prevention [3], and perhaps generally increasing longevity. Alternatively, the pathophysiology of 
left ventricular remodeling and prognosis in acute MI survivors remains incompletely 
understood. This problem is further illustrated by the results of recent clinical trials in which 
novel therapies have not been associated with improvements in cardiac prognosis [5,6]. Given 
the public health burden of heart failure post-MI and mixed results with new therapies, do we 
need to rethink the approach to risk stratification for our post-MI patients?  
In this regard, the article by Reinstadler et al. [7] is timely. They undertook a post-hoc analysis of 
left ventricular function and tissue characteristics in the infarct and remote zones revealed by 
multi-parametric cardiac magnetic resonance (CMR) scans obtained within the first week of an 
acute STEMI in a cohort of 255 patients. There are two main results. The first is the independent 
prognostic importance of the tissue changes in the myocardial remote zone, as revealed by native 
T1 mapping, for recurrent major adverse cardiac events (MACE). The second is the proposition 
of an integrative approach in which data on left ventricular function and pathology within infarct 
and remote zones can be assimilated within a prognostic model for individualized prediction of 
cardiac prognosis. Thus, rather than a focus on one parameter, the totality of parameters with 
distinct prognostic significance for MACE are statistically modeled to optimize risk prediction 
over and above the prognostic value of any one of the parameters in isolation.  
Cardiac imaging of a post-MI patient is typically focused on left ventricular function, infarct size 
and complications [8]. So why might the myocardial remote zone be worthy of focused attention 
in the clinical report? There is an extensive literature on the pathophysiological significance of 
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the myocardial remote zone post-MI [9-12]. Acute MI triggers a systemic acute phase response, 
and neutrophils and monocyte / macrophages track to infarct and remote myocardial tissues from 
reticuloendothelial stores [9,10]. Macrophage cytokine production represents a stress response 
post-MI leading to apoptosis, extracellular collagen degradation and loss of microvessels [9]. 
Potentially, inflammation may be the driver for maladaptive remodeling [11,12]. The magnitude 
of systemic inflammation is prognostically important post-MI [12] and evidence-based therapies 
for MI may reduce inflammatory activation [13]. 
So what is native T1 mapping? Human tissue has fundamental magnetic properties, including the 
longitudinal (spin-lattice) proton relaxation time (native T1 in milliseconds). Native T1 is 
influenced by water content, binding with macromolecules and cell composition [14]. 
Myocardial water and inflammatory cell content increases as a result of injury [15], and longer 
T1 times are a biomarker of tissue injury [11,12].  
In a recent natural history study, we enrolled 288 patients with acute reperfused STEMI who 
underwent CMR 2 days and 6 months post-MI and follow-up to 3 years (see Figures 1 & 2 from 
[12]). Myocardial remote zone native T1 was approximately 10 ms higher on average in patients 
with ECG evidence of reperfusion injury and increased by approximately 10 ms, on average, for 
every 1x109/L increase in peak monocyte count within 2 days of admission. Remote zone native 
T1 (ms) was independently associated with LV remodeling, as revealed by CMR, the within-
subject changes in NT-proBNP concentration at 6 months, and MACE and all-cause death or 
heart failure hospitalization in the longer term. The study by Reinstadler et al. [7] reported 
similar findings for MACE. Considering clinical translation, native T1 mapping could be 
considered as a surrogate biomarker in randomized controlled trials of interventions that are 
intended to prevent adverse remodeling. 
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The infarct zone hypothesis states that limiting infarct size early after acute MI by timely 
reperfusion increases myocardial salvage, prevents infarct complications, such as microvascular 
obstruction, and improves prognosis. However, in our experience, this infarct zone hypothesis is 
insufficient to fully account for adverse left ventricular remodeling post-MI, and adaptive 
changes within the infarcted heart are multifactorial. Homeostatic changes within remote 
myocardial tissue seem to have a pivotal role in adaptive LV remodeling. An inadequate 
biomechanical response within the remote zone will result in pump failure and ventricular 
dilatation. Accordingly, the ‘remote zone hypothesis’ identifies homeostatic changes within 
remote zone tissue as having a pivotal role in adaptive LV remodeling, and a unifying approach 
would integrate the imaging findings within the infarct and remote zones. Reinstadler et al. 
integrated these parameters into one prognostic model that more fully exploits the unique 
biomarker parameters provided by a multi-parametric CMR scan [7,8,12]. There were also some 
limitations in this study. Their population was derived from a clinical trial (LIPSIA-
CONDITIONING, NCT02158468), the duration of follow-up was only 6 months, and the model 
included both infarct size and myocardial salvage index which are inextricably linked. Further 
research is warranted to assess the external validity of this CMR prognostic model. 
So, how to mend a broken heart? Future prognostic studies should confirm the external validity 
of this (or any other) CMR model, and also confirm whether or not an integrative imaging model 
might have greater prognostic value for cardiac events post-MI than one that includes clinical 
parameters without CMR, or even, simply, NT-proBNP. Since CMR early post-MI reveals 
myocardial function and pathology in a single scan, we hypothesise that an integrative CMR 
model will be more informative for prognostication than those other approaches. Should this be 
the case, then the CMR approach may have clinically-useful applications for patient-specific risk 
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assessment and stratification for more (or less) intensive therapy. Similarly, clinical trials of 
novel therapies could invoke a stratified approach to selectively enroll patients identified using a 
CMR model to be at higher risk of adverse cardiac outcome. In this sense, multi-parametric 
CMR has an emerging role for personalized medicine of post-MI patients. 
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